NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

白细胞介素2受体次单元α (TAC抗原/p55/CD25/IL2RA):开发平台分析

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品编码 361640
出版日期 内容资讯 英文 74 Pages
订单完成后即时交付
价格
白细胞介素2受体次单元α (TAC抗原/p55/CD25/IL2RA):开发平台分析 Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019
出版日期: 2019年12月27日内容资讯: 英文 74 Pages
简介

本报告提供全球各国的白细胞介素2受体次单元α (TAC抗原或p55或CD25或IL2RA)的开发中产品的开发情形相关分析,产品开发、上市的最新趋势,及临床实验的各阶段的产品一览,主要企业简介,主要药物概要,最新的产业趋势等资讯,为您概述为以下内容。

目录

简介

  • 分析范围

白细胞介素2受体次单元α (TAC抗原/p55/CD25/IL2RA)概要

治疗药的开发

  • 白细胞介素2受体次单元α (TAC抗原/p55/CD25/IL2RA的)开发中产品:概要

在白细胞介素2受体次单元α (TAC抗原/p55/CD25/IL2RA):各企业开发中的治疗药

  • 临床实验的各阶段
  • 各治疗领域
  • 各症状

开发中产品的概要

  • 后期阶段的产品
  • 初期阶段的产品

各企业开发中的治疗药

治疗药的评估

  • 单剂治疗药/并用治疗药的情况
  • 各作用机制
  • 各投药法
  • 各分子类型

开发治疗药的企业

  • AbbVie Inc.
  • Alkermes Plc
  • APT Therapeutics, Inc.
  • Mabtech Limited
  • Philogen S.p.A.

药物简介

  • APT-602
    • 产品概要
    • 作用机制
    • 研究开发 (R&D)的发展情形
  • basiliximab
  • basiliximab的生技改良药
  • daclizumab
  • Darleukin
  • RDB-1450

开发暂停的产品

值得注意的最新趋势、新闻稿 (共15件)

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC2076TDB

Summary

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 3 and 5 respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Dermatology and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Plaque Psoriasis (Psoriasis Vulgaris), Renal Cell Carcinoma, Solid Tumor, Systemic Lupus Erythematosus, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Diabetic Nephropathy, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Inflammation, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Relapsed Acute Myeloid Leukemia, Skin Cancer, Soft Tissue Sarcoma, Stroke, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).

The latest report Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
  • Alkermes Plc
  • Anaveon AG
  • APT Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Courier Therapeutics Inc
  • Mabtech Ltd
  • Medicenna Therapeutics Corp
  • Nektar Therapeutics
  • Philogen SpA
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
  • ALKS-4230 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APT-602 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • basiliximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • basiliximab biobetter - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CC-92252 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • daclizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • darleukin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • daromun - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDNA-209 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NARA-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NKTR-358 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teleukin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 10, 2019: Nektar Therapeutics presents data from first-in-human phase 1a study on novel T regulatory cell stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
  • Nov 08, 2019: Alkermes announces new data from ALKS 4230 clinical development program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
  • Nov 04, 2019: Alkermes to present data from ALKS 4230 clinical development program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
  • Oct 21, 2019: Alkermes announces clinical collaboration with Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
  • Oct 07, 2019: Nektar Therapeutics announces initiation of two clinical studies of novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with psoriasis and atopic dermatitis
  • Jun 13, 2019: First-in-Human data presented from Phase 1a Study of NKTR-358, a novel t regulatory cell stimullator, at Annual European Congress of Rheumatology
  • Jun 12, 2019: Alkermes advances ALKS 4230 into monotherapy expansion Phase of ARTISTRY-1 in patients with renal cell carcinoma or melanoma
  • Jun 11, 2019: Nektar Therapeutics to host webcast conference call with immunology expert for analysts & investors during 2019 European Congress of Rheumatology (EULAR 2019)
  • Feb 26, 2019: Alkermes initiates clinical study of ALKS 4230 administered subcutaneously in patients with advanced solid tumors
  • Nov 06, 2018: Alkermes presents new data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
  • Sep 11, 2018: Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumours
  • Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
  • May 18, 2018: EMA review of Zinbryta confirms medicine's risks outweigh its benefits
  • May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
  • Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Alkermes Plc, H2 2019
  • Pipeline by Anaveon AG, H2 2019
  • Pipeline by APT Therapeutics Inc, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Courier Therapeutics Inc, H2 2019
  • Pipeline by Mabtech Ltd, H2 2019
  • Pipeline by Medicenna Therapeutics Corp, H2 2019
  • Pipeline by Nektar Therapeutics, H2 2019
  • Pipeline by Philogen SpA, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019